Skip to main content
. Author manuscript; available in PMC: 2017 Apr 18.
Published in final edited form as: Plasma Med. 2016;6(2):135–177. doi: 10.1615/PlasmaMed.2016018618

Fig. 5.

Fig. 5

The basal ROS levels are higher for cancer cells compared to normal cells, thus application of exogenous ROS species in plasma-activated solutions will push cancer cells over the ROS threshold, while normal cells are able to maintain homeostasis via antioxidant pathways. The actual ROS threshold level will vary depending upon the cell type and specific ROS involved.